These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33630085)

  • 1. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
    Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
    JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
    Machado MAÁ; de Moura CS; Chan K; Curtis JR; Hudson M; Abrahamowicz M; Jamal R; Pilote L; Bernatsky S
    Sci Rep; 2020 Sep; 10(1):14607. PubMed ID: 32884119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
    Beaver JA; Hazarika M; Mulkey F; Mushti S; Chen H; He K; Sridhara R; Goldberg KB; Chuk MK; Chi DC; Chang J; Barone A; Balasubramaniam S; Blumenthal GM; Keegan P; Pazdur R; Theoret MR
    Lancet Oncol; 2018 Feb; 19(2):229-239. PubMed ID: 29361469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer.
    Griffith SD; Tucker M; Bowser B; Calkins G; Chang CJ; Guardino E; Khozin S; Kraut J; You P; Schrag D; Miksad RA
    Adv Ther; 2019 Aug; 36(8):2122-2136. PubMed ID: 31140124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
    Wang M; Chen C; Jemielita T; Anderson J; Li XN; Hu C; Kang SP; Ibrahim N; Ebbinghaus S
    J Immunother Cancer; 2019 Feb; 7(1):39. PubMed ID: 30736858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
    Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
    Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research.
    Feinberg BA; Bharmal M; Klink AJ; Nabhan C; Phatak H
    Future Oncol; 2018 Nov; 14(27):2841-2848. PubMed ID: 29848070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non-Small Cell Lung Cancer Treated With First-Line Therapy.
    Ma X; Bellomo L; Hooley I; Williams T; Samant M; Tan K; Segal B; Bourla AB
    JAMA Netw Open; 2022 May; 5(5):e229655. PubMed ID: 35552726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
    Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
    Schliep S; Agaimy A; Cavallaro A; Kiesewetter F; Schuler G; Heinzerling L
    J Immunother Cancer; 2018 Jan; 6(1):2. PubMed ID: 29332608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.
    Uhrig M; Hassel JC; Schlemmer HP; Ganten MK
    Acad Radiol; 2013 Apr; 20(4):423-9. PubMed ID: 23498982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
    Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
    Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
    Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.
    Colen RR; Rolfo C; Ak M; Ayoub M; Ahmed S; Elshafeey N; Mamindla P; Zinn PO; Ng C; Vikram R; Bakas S; Peterson CB; Rodon Ahnert J; Subbiah V; Karp DD; Stephen B; Hajjar J; Naing A
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.